IL‑6 prevents CXCL8‑induced stimulation of EpCAM expression in ovarian cancer cells

Kapka‑Skrzypczak,Lucyna; Popek,Sylwia; Sawicki,Krzysztof; Drop,Bartłomiej; Czajka,Magdalena; Jodłowska‑Jędrych,Barbara; Matysiak‑Kucharek,Magdalena; Furman‑Toczek,Dominika; Zagórska‑Dziok,Martyna; Kruszewski,Marcin

doi:10.3892/mmr.2019.9890

IL‑6 prevents CXCL8‑induced stimulation of EpCAM expression in ovarian cancer cells

Authors:
- Lucyna Kapka‑Skrzypczak
- Sylwia Popek
- Krzysztof Sawicki
- Bartłomiej Drop
- Magdalena Czajka
- Barbara Jodłowska‑Jędrych
- Magdalena Matysiak‑Kucharek
- Dominika Furman‑Toczek
- Martyna Zagórska‑Dziok
- Marcin Kruszewski
View Affiliations

Affiliations: Department of Medical Biology and Translational Research, Faculty of Medicine, University of Information Technology and Management, 35‑225 Rzeszow, Poland, Department of Cancer Genetics with Cytogenetics Laboratory, Medical University of Lublin, 20‑080 Lublin, Poland, Department of Molecular Biology and Translational Research, Institute of Rural Health, 0‑090 Lublin, Poland, Department of Informatics and Medical Statistics, Faculty of Health Sciences, Medical University, 20‑090 Lublin, Poland, Department of Histology and Embryology with Experimental Cytology Unit, Medical University of Lublin, 20‑080 Lublin, Poland
Published online on: January 23, 2019 https://doi.org/10.3892/mmr.2019.9890
Pages: 2317-2322

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epithelial cell adhesion molecule (EpCAM), which is expressed in the majority of epithelial tissues, exhibits tumor growth promoting abilities and is overexpressed in human epithelial ovarian cancer. Therefore, EpCAM is considered to be a promising target for specific immune‑based therapies. The present study evaluated the role of IL‑6 and IL‑8 in the expression of EpCAM in the A2780 human ovarian cancer cell line. Furthermore, the cellular localization of the EpCAM protein in A2780 cells was determined and the effect of EpCAM inhibition on the proliferation of the A2780 cells was investigated. An MTT assay demonstrated that blocking EpCAM with anti‑EPCAM antibodies had no effect on cellular metabolic activity (proliferation). Gene expression analysis revealed that IL‑8 increased EpCAM expression, whereas IL‑6 and the combination of IL‑6/IL‑8 had no effect on EpCAM expression. Immunofluorescence analysis confirmed that EpCAM is expressed on A2780 cell membranes. The present results demonstrated that IL‑8 increased EpCAM expression at the mRNA level in ovarian cancer cells and suggested a potential role of IL‑6 as an inhibitor of IL‑8‑stimulated EpCAM expression.

View Figures

View References

1	Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, Baeuerle PA, Mueller-Holzner E, Marth C, Gastl G and Zeimet AG: Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol. 103:483–488. 2006. View Article : Google Scholar : PubMed/NCBI
2	Massoner P, Thomm T, Mack B, Untergasser G, Martowicz A, Bobowski K, Klocker H, Gires O and Puhr M: EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205. Br J Cancer. 111:955–964. 2014. View Article : Google Scholar : PubMed/NCBI
3	Köbel M, Kolloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, et al: Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies. PLoS Med. 5:e2322008. View Article : Google Scholar : PubMed/NCBI
4	Fan Q, Cheng JC, Qui X, Chang HM and Leung PC: EpCAM is up-regulated by EGF via ERK1/2 signaling and suppresses human epithelial ovarian cancer cell migration. Biochem Biophys Res Commun. 457:256–261. 2015. View Article : Google Scholar : PubMed/NCBI
5	Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, Falchetti M, Odicino FE, Pecorelli S and Santin AD: Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol Oncol. 103:405–416. 2006. View Article : Google Scholar : PubMed/NCBI
6	English DP, Bellone S, Schwab CL, Roque DM, Lopez S, Bortolomai I, Cocco E, Bonazzoli E, Chatterjee S, Ratner E, et al: Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Cancer. 121:403–412. 2015. View Article : Google Scholar : PubMed/NCBI
7	Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, Cole DJ and Gillanders WE: EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 64:5818–5824. 2004. View Article : Google Scholar : PubMed/NCBI
8	Thibault B, Castells M, Delord JP and Couderc B: Ovarian cancer microenvironment: Implications for cancer dissemination and chemoresistance acquisition. Cancer Metastasis Rev. 33:17–39. 2014. View Article : Google Scholar : PubMed/NCBI
9	Stronach EA, Cunnea P, Turner C, Guney T, Aiyappa R, Jeyapalan S, de Sousa CH, Browne A, Magdy N, Studd JB, et al: The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma. Oncotarget. 6:31593–31603. 2015. View Article : Google Scholar : PubMed/NCBI
10	Loose D and Van de Wiele C: The immune system and cancer. Cancer Biother Radiopharm. 24:369–376. 2009. View Article : Google Scholar : PubMed/NCBI
11	Kapka-Skrzypczak L, Popek S, Sawicki K, Wolińska E, Czajka M and Skrzypczak M: Effect of IL-6 and IL-8 on the expression of the complement activation inhibitors MAC-inhibitory protein and decay-accelerating factor in ovarian cancer A2780 cells. Oncol Lett. 12:1507–1512. 2016. View Article : Google Scholar : PubMed/NCBI
12	Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Shioppa T, Robinson SC, Gallagher WM, et al: A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res. 72:66–75. 2012. View Article : Google Scholar : PubMed/NCBI
13	Bonneau C, Rouzier R, Geyl C, Cortez A, Castela M, Lis R, Daraï E and Touboul C: Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma. Gynecol Oncol. 136:112–120. 2015. View Article : Google Scholar : PubMed/NCBI
14	Yin J, Zeng F, Wu N, Kang K, Yang Z and Yang H: Interleukin-8 promotes human ovarian cancer cell migration by epithelial-mesenchymal transition induction in vitro. Clin Transl Oncol. 17:365–370. 2015. View Article : Google Scholar : PubMed/NCBI
15	Matysiak M, Kapka-Skrzypczak L, Jodłowska-Jędrych B and Kruszewski M: EMT promoting transcription factors as prognostic markers in human breast cancer. Arch Gynecol Obstet. 295:817–825. 2017. View Article : Google Scholar : PubMed/NCBI
16	Luo Z, Wang Q, Lau WB, Lau B, Xu L, Zhao L, Yang H, Feng M, Xuan Y, Yang Y, et al: Tumor microenvironment: The culprit for ovarian cancer metastasis? Cancer Lett. 377:174–182. 2016. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 26:402–408. 2001. View Article : Google Scholar
18	Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S and Santin AD: Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: Implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer. 19:860–866. 2009. View Article : Google Scholar : PubMed/NCBI
19	Münz M, Kieu C, Mack B, Schmitt B, Zeidler R and Gires O: The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene. 23:5748–5758. 2004. View Article : Google Scholar : PubMed/NCBI
20	Münz M, Zeidler R and Gires O: The tumor-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP. Cancer Lett. 225:151–157. 2005. View Article : Google Scholar : PubMed/NCBI
21	Ni J, Cozzi P, Hao J, Beretov J, Chang L, Duan W, Shigdar S, Delprado W, Graham P, Bucci J, et al: Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int J Biochem Cell Biol. 45:2736–2748. 2013. View Article : Google Scholar : PubMed/NCBI
22	Li Y, Farmer RW, Yang Y and Martin RC: Epithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: A target of chemoresistence. BMC Cancer. 16:2282016. View Article : Google Scholar : PubMed/NCBI
23	Zheng J, Zhao L, Wang Y, Zhao S and Cui M: Clinicopathology of EpCAM and EGFR in human epithelial ovarian carcinoma. Open Med (Wars). 12:39–44. 2017.PubMed/NCBI
24	Tayama S, Motohara T, Narantuya D, Li C, Fujimoto K, Sakaguchi I, Tashiro H, Saya H, Nagano O and Katabuchi H: The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer. Oncotarget. 8:44312–44325. 2017. View Article : Google Scholar : PubMed/NCBI
25	Bokemeyer C: Catumaxomab-trifunctional anti-EpCAM antibody used to treat malignant ascites. Expert Opin Biol Ther. 10:1259–1269. 2010. View Article : Google Scholar : PubMed/NCBI
26	https://www.ema.europa.eu/documents/public-statement/publicstatement-removab-withdrawal-marketing-authorisation-european-union_en.pdf20–11. 2018
27	Zheng X, Fan X, Fu B, Zheng M, Zhang A, Zhong K, Yan J, Sun R, Tian Z and Wei H: EpCAM inhibition sensitizes chemoresistant leukemia to immune surveillance. Cancer Res. 77:482–493. 2017. View Article : Google Scholar : PubMed/NCBI
28	Wang Y, Guo XQ, Niu XL, Wu J, Zhu YQ and Mao LQ: Relationship of IL-6 and IL-8 secretion in epithelial ovarian cancer cell lines with their sensitivity to tamoxifen as well as MAPK, Akt and estrogen receptor phosphorylation. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 26:21–24. 2010.(In Chinese). PubMed/NCBI
29	Asschert JG, Vellenga E, Ruiters MH and de Vries EG: Regulation of spontaneous and TNF/INF-induced IL-6 expression in two human ovarian-carcinoma cell lines. Int J Cancer. 82:244–249. 1999. View Article : Google Scholar : PubMed/NCBI
30	Li FF, Shen J, Shen HJ, Zhang X, Cao R, Zhang Y, Qui Q, Lin XX, Xie YC, Zhang LH, et al: Shp2 plays an important role in acute cigarette smoke-mediated lung inflammation. J Immunol. 189:3159–3167. 2012. View Article : Google Scholar : PubMed/NCBI
31	Ke Y, Zhang EE, Hagihara K, Wu D, Pang Y, Klein R, Curran T, Ranscht B and Feng GS: Deletion of Shp2 in the brain leads to defective proliferation and differentiation in neural stem cells and early postnatal lethality. Mol Cell Biol. 27:6706–6717. 2007. View Article : Google Scholar : PubMed/NCBI
32	Lehmann U, Schmitz J, Weissenbach M, Sobota RM, Hortner M, Friederichs K, Behrmann I, Tsiaris W, Sasaki A, Schneider-Mergener J, et al: SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem. 278:661–671. 2003. View Article : Google Scholar : PubMed/NCBI
33	Fischer P, Lehmann U, Sobota RM, Schmitz J, Niemand C, Linnemann S, Haan S, Behrmann I, Yoshimura A, Johnston JA, et al: The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signaling. Biochem J. 378:449–460. 2004. View Article : Google Scholar : PubMed/NCBI
34	Mamik MK and Ghorpade A: Src homology-2 domain-containing protein tyrosine phosphatase (SHP) 2 and p38 regulate the expression of chemokine CXCL8 in human astrocytes. PLoS One. 7:e455962012. View Article : Google Scholar : PubMed/NCBI
35	Schafer ZT and Brugge JS: IL-6 involvement in epithelial cancers. J Clin Invest. 117:3660–3663. 2007. View Article : Google Scholar : PubMed/NCBI
36	Waugh DJ and Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
37	Feng GS: Shp-2 tyrosine phosphatase: Signaling one cell or many. Exp Cell Res. 253:47–54. 1999. View Article : Google Scholar : PubMed/NCBI
38	You M, Yu DH and Feng GS: Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol. 19:2416–2424. 1999. View Article : Google Scholar : PubMed/NCBI